Alembic Pharmaceuticals · NSE: APLLTD · BSE: 533573
Q4 FY24 results · Jan–Mar 2024
Alembic Pharmaceuticals reported revenue from operations of ₹1,516.98 crore (up 7.9% from Q4 FY23) and net profit of ₹178.21 crore (up 16.8% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,516.98 | 1,406.45 | +7.9% | 1,630.57 | −7.0% |
| Other income | 3.60 | 0.89 | +304.5% | 2.89 | +24.3% |
| Total income | 1,520.58 | 1,407.34 | +8.0% | 1,633.46 | −6.9% |
| Profit before share of associates & JVs and tax | 183.24 | 124.61 | +47.0% | 184.63 | −0.8% |
| Share of profit/(loss) of associates & JVs | (0.39) | (8.45) | (0.05) | ||
| Net profit for the period | 178.21 | 152.60 | +16.8% | 180.46 | −1.2% |
| EPS, basic (₹) | 9.07 | 7.76 | +16.8% | 9.18 | −1.2% |
| Net margin (%) | 11.7 | 10.8 | 11.1 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,474.55 | 1,307.12 | +12.8% | 1,588.39 | −7.2% |
| Other income | 7.22 | 1.96 | +268.7% | 3.30 | +118.8% |
| Total income | 1,481.78 | 1,309.08 | +13.2% | 1,591.69 | −6.9% |
| Profit before tax | 216.16 | 84.01 | +157.3% | 256.70 | −15.8% |
| Net profit for the period | 201.87 | 130.54 | +54.6% | 233.24 | −13.5% |
| EPS, basic (₹) | 10.27 | 6.64 | +54.6% | 11.87 | −13.5% |
| Net margin (%) | 13.7 | 10.0 | 14.7 |
Consolidated
- Filed with BSE
- 10 May 2024, 11:54 IST
- Board meeting
- 09 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 May 2024, 11:54 IST
- Board meeting
- 09 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE